Survival after lumpectomy and mastectomy for early stage invasive breast cancer: The effect of age and hormone receptor status

Cancer

Volumn 119, Issue 17, 2013, Pages 3253-3254

  De Glas, Nienke A ^a   Kiderlen, Mandy ^a   Liefers, Gerrit Jan ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE RECEPTOR;

BREAST CANCER; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COMORBIDITY; FUNCTIONAL DISEASE; GERIATRIC PATIENT; HUMAN; LETTER; MASTECTOMY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT RESPONSE; BREAST TUMOR; FEMALE; MORTALITY; NOTE; SEGMENTAL MASTECTOMY;

BREAST NEOPLASMS; FEMALE; HUMANS; MASTECTOMY; MASTECTOMY, SEGMENTAL;

EID: 84882694285     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28184     Document Type: Letter

References (5)

1. Hwang ES, Lichtensztajn DY, Gomez SL, Fowble B, Clarke CA,. Survival after lumpectomy and mastectomy for early stage invasive breast cancer: the effect of age and hormone receptor status. Cancer. 2013; 119: 1402-1411.
2. Louwman WJ, Janssen-Heijnen ML, Houterman S, et al. Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study. Eur J Cancer. 2005; 41: 779-785.
3. Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS,. Under representation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341: 2061-2067.
4. Vandenbroucke JP,. When are observational studies as credible as randomised trials? Lancet. 1004; 363: 1728-1731.
5. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 366: 2087-2106.